Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • First Disclosures
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Therapeutic Agents: Small Molecule Kinase Inhibitors

Abstract A275: Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors.

Carmen Blanco Aparicio, Oliver Renner, Elena Gomez-Casero, Antonio Cebriá, Nuria Ajenjo, Enara Aguirre, David Cebrián, Mª Carmen Rodriguez de Miguel, Belén Pequeño, MªIsabel Albarrán, Rosario Riesco, Ana Belén García, Rosa Alvarez, Michael O'Neill, Sonia Martinez and Joaquin Pastor
Carmen Blanco Aparicio
1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oliver Renner
1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena Gomez-Casero
1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Antonio Cebriá
1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nuria Ajenjo
1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enara Aguirre
1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Cebrián
1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mª Carmen Rodriguez de Miguel
1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Belén Pequeño
1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MªIsabel Albarrán
1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosario Riesco
1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ana Belén García
1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosa Alvarez
1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael O'Neill
2Inflection Bioscience, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonia Martinez
1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joaquin Pastor
1Spanish National Cancer Research Centre (CNIO), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1535-7163.TARG-13-A275 Published November 2013
  • Article
  • Info & Metrics
Loading

Abstract

The PI3K/AKT pathway is commonly activated in human cancer. Multiple small-molecule inhibitors have been developed to target PI3K/mTOR or AKT kinases, but the efficacy of these drugs is compromised by the stimulation of compensatory signaling pathways. The redundancy of oncogenic signaling pathways provides back-up mechanisms that allow cancer cells to escape to targeted therapies. One example of such compensatory pathways is that driven by PIM kinases, which produce parallel oncogenic signals to AKT and mTOR and share several downstream molecular targets. In fact, in mouse lymphoma models chemoresistance to doxorubicin caused by AKT is readily reversed by rapamycin, but PIM mediated resistance is refractory to mTORC1 inhibition. Moreover, PIM2 kinase can confer resistance of primary hematopoietic cells to rapamycin treatment. Furthermore, PIM 1 mediates resistance to AKT and PI3K/mTOR inhibition and suggests co-targeting to improve the efficacy of PI3K/AKT/mTOR inhibitors in anticancer therapy. The PI3K/AKT/mTOR and PIM pathways are activated and seem to be relevant for tumor progression in many lymphomas, leukemias and in some solid tumors. We have previously reported that the combination of PI3K inhibitor GDC-0941 with a PIM selective inhibitor, ETP-45299, was strongly synergistic in antiproliferation experiments in MV-4-11 AML cells. Therefore, combination of such activities in a single molecule might have the potential to achieve better clinical efficacy and prevent/suppress resistance in comparison with classical PI3K/AKT/mTOR inhibitors. During the course of our investigations in this field we have identified a new chemical series of compounds with dual (PIM/PI3K) and triple activity (PIM/PI3K/mTOR inhibitors). (WO2012/156756). In this work, we show the biochemical, cellular and in vivo characterization of dual PIM/PI3K ETP-539/(IBL-202) and triple PIM/PI3K/mTOR ETP-339/(IBL-301) inhibitors. These optimized lead compounds are low nanomolar pan PIM/PI3K and pan PIM/PI3K/mTOR inhibitors respectively. These dual and triple inhibitors show excellent kinase selectivity profile against a panel of 456 kinases. Both compounds have been profiled for their antiproliferative behavior. We have identified leukemia, lymphoma, colon, and NSCLC lines which exhibit a strong sensitivity to dual and triple inhibition with GI80 between 5-10 times more potent than PIM or PI3K selective reference inhibitors. Mechanistically, cells respond to dual and triple inhibitors with a clear cell cycle arrest and marked apoptosis in AML and NSCLC cell lines, and strong down regulation of biomarkers. Our dual and triple inhibitors are optimized with respect to their in vitro ADME properties and have excellent oral bioavailability. These inhibitors have been tested in vivo in xenograft (MV4:11 AML) and transgenic (KRAsV12NSCLC) cancer mouse models. Both compounds have demonstrated down regulation of biomarkers associated with their targeted profile and significant antitumor efficacy in both models after oral administration. These inhibitors have been well tolerated, with no signs of toxicity even 20 times above the efficacious dose.

These results provide the rationale for further preclinical development of ETP-539/(IBL-202 and ETP-339/(IBL-301) and the basis for a potential clinical use in AML and NSCLC tumors.

Citation Information: Mol Cancer Ther 2013;12(11 Suppl):A275.

Citation Format: Carmen Blanco Aparicio, Oliver Renner, Elena Gomez-Casero, Antonio Cebriá, Nuria Ajenjo, Enara Aguirre, David Cebrián, Ma Carmen Rodriguez de Miguel, Belén Pequeño, MaIsabel Albarrán, Rosario Riesco, Ana Belén García, Rosa Alvarez, Michael O'Neill, Sonia Martinez, Joaquin Pastor. Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013;12(11 Suppl):Abstract nr A275.

  • Copyright © November 2013, American Association for Cancer Research
Previous
Back to top
Molecular Cancer Therapeutics: 12 (11 Supplement)
November 2013
Volume 12, Issue 11 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A275: Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors.
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A275: Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors.
Carmen Blanco Aparicio, Oliver Renner, Elena Gomez-Casero, Antonio Cebriá, Nuria Ajenjo, Enara Aguirre, David Cebrián, Mª Carmen Rodriguez de Miguel, Belén Pequeño, MªIsabel Albarrán, Rosario Riesco, Ana Belén García, Rosa Alvarez, Michael O'Neill, Sonia Martinez and Joaquin Pastor
Mol Cancer Ther November 1 2013 (12) (11 Supplement) A275; DOI: 10.1158/1535-7163.TARG-13-A275

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A275: Co-targeting PIM and PI3K/mTOR pathways with a single molecule: Novel orally available combined PIM/PI3K and PIM/PI3K/mTOR kinase inhibitors.
Carmen Blanco Aparicio, Oliver Renner, Elena Gomez-Casero, Antonio Cebriá, Nuria Ajenjo, Enara Aguirre, David Cebrián, Mª Carmen Rodriguez de Miguel, Belén Pequeño, MªIsabel Albarrán, Rosario Riesco, Ana Belén García, Rosa Alvarez, Michael O'Neill, Sonia Martinez and Joaquin Pastor
Mol Cancer Ther November 1 2013 (12) (11 Supplement) A275; DOI: 10.1158/1535-7163.TARG-13-A275
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Therapeutic Agents: Small Molecule Kinase Inhibitors

  • Abstract C075: The use of 4HF Cancer Data Miner platform for an in Silico pharmacogenomic study predicting tumor response to the CDK4/6 inhibitor Palbociclib
  • Abstract C088: Chemical phosphoproteomics systematically identifies circuitries of kinase networks in cancer cells and predicts their response to kinase inhibitors
  • Abstract LB-C12: Derazantinib (DZB): A dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer
Show more Therapeutic Agents: Small Molecule Kinase Inhibitors

Therapeutic Agents: Small Molecule Kinase Inhibitors: Poster Presentations - Proffered Abstracts

  • Abstract C075: The use of 4HF Cancer Data Miner platform for an in Silico pharmacogenomic study predicting tumor response to the CDK4/6 inhibitor Palbociclib
  • Abstract C088: Chemical phosphoproteomics systematically identifies circuitries of kinase networks in cancer cells and predicts their response to kinase inhibitors
  • Abstract LB-C12: Derazantinib (DZB): A dual FGFR/CSF1R-inhibitor active in PDX-models of urothelial cancer
Show more Therapeutic Agents: Small Molecule Kinase Inhibitors: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement